Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?
Eye (Lond)
.
2024 Feb;38(2):244-245.
doi: 10.1038/s41433-023-02698-3.
Epub 2023 Aug 30.
Authors
Ashish Sharma
1
,
Anat Loewenstein
2
,
Nikulaa Parachuri
3
,
Nilesh Kumar
4
,
Alok Rasal
5
,
Francesco Bandello
6
,
Baruch D Kuppermann
7
Affiliations
1
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, Tamil Nadu, India. drashish79@hotmail.com.
2
Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.
3
Department of Vitreoretina, Sankara eye Hospital, Coimbatore, Tamil Nadu, India.
4
Madhavi Netralaya, Ara, Bihar, India.
5
Intas Pharmaceuticals, Ahmedabad, Gujarat, India.
6
University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
7
Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA.
PMID:
37648725
PMCID:
PMC10810884
(available on
2025-02-01
)
DOI:
10.1038/s41433-023-02698-3
No abstract available
MeSH terms
Biosimilar Pharmaceuticals* / therapeutic use
Humans
Syringes
Substances
Biosimilar Pharmaceuticals